DK0769954T3 - Kvalitetssikret lægemiddel indeholdende et eller flere plasmaderivater - Google Patents

Kvalitetssikret lægemiddel indeholdende et eller flere plasmaderivater

Info

Publication number
DK0769954T3
DK0769954T3 DK96910855T DK96910855T DK0769954T3 DK 0769954 T3 DK0769954 T3 DK 0769954T3 DK 96910855 T DK96910855 T DK 96910855T DK 96910855 T DK96910855 T DK 96910855T DK 0769954 T3 DK0769954 T3 DK 0769954T3
Authority
DK
Denmark
Prior art keywords
plasma derivatives
assured
quality
plasma
drug containing
Prior art date
Application number
DK96910855T
Other languages
English (en)
Other versions
DK0769954T4 (da
Inventor
Friedrich Dorner
Johann Eibl
Otto Schwarz
Herwig Igel
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3499516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0769954(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of DK0769954T3 publication Critical patent/DK0769954T3/da
Publication of DK0769954T4 publication Critical patent/DK0769954T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
DK96910855.4T 1995-05-08 1996-05-06 Kvalitetssikret lægemiddel indeholdende et eller flere plasmaderivater DK0769954T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0077895A AT406019B (de) 1995-05-08 1995-05-08 Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate
PCT/AT1996/000089 WO1996035437A1 (de) 1995-05-08 1996-05-06 Qualitätsgesichertes arzneimittel, enthaltend ein oder mehrere plasmaderivate

Publications (2)

Publication Number Publication Date
DK0769954T3 true DK0769954T3 (da) 2003-11-17
DK0769954T4 DK0769954T4 (da) 2011-04-04

Family

ID=3499516

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96910855.4T DK0769954T4 (da) 1995-05-08 1996-05-06 Kvalitetssikret lægemiddel indeholdende et eller flere plasmaderivater

Country Status (10)

Country Link
EP (1) EP0769954B2 (da)
JP (2) JPH10502943A (da)
AT (2) AT406019B (da)
CA (1) CA2191475C (da)
DE (1) DE59610626D1 (da)
DK (1) DK0769954T4 (da)
ES (1) ES2203688T5 (da)
IL (1) IL118188A (da)
NO (1) NO322186B1 (da)
WO (1) WO1996035437A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780222A (en) 1995-04-10 1998-07-14 Alpha Therapeutic Corporation Method of PCR testing of pooled blood samples
AT403477B (de) * 1996-04-30 1998-02-25 Immuno Ag Biologisches material frei von viralen und molekularen pathogenen und verfahren zur herstellung
WO1999023250A2 (de) 1997-11-04 1999-05-14 Roche Diagnostics Gmbh Spezifisches und sensitives nukleinsäurenachweisverfahren
DE19752898A1 (de) * 1997-11-28 1999-08-05 Centeon Pharma Gmbh Verfahren zum Nachweis hoher Vierenkonzentrationen im Blutplasma und/oder Blutserum mittels der Polymerasekettenreaktion
AT407160B (de) * 1998-06-04 2001-01-25 Immuno Ag Verfahren zur bestimmung von antigenen
CA2362513C (en) 1999-02-12 2011-04-26 Baxter Aktiengesellschaft A method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method
AT410218B (de) 1999-08-20 2003-03-25 Baxter Ag Verfahren zur herstellung eines qualitätsgesicherten pools biologischer proben
CN106916802B (zh) * 2003-12-01 2022-03-25 诺和诺德医疗保健公司 液体因子vii组合物的病毒过滤
DE102005054206B4 (de) * 2005-11-14 2010-07-15 Roth, Willi, Prof. Dr. Verfahren und Vorrichtung zum automatisierten Bearbeiten von gepoolten Proben
RU2730538C2 (ru) * 2015-09-02 2020-08-24 ЕП МИНЕРАЛЗ, ЭлЭлСи Регенерированные вещества, пригодные для обработки полученных при брожении жидкостей

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0447984A1 (en) * 1990-03-20 1991-09-25 Abbott Laboratories Hyperimmune globulin against hepatitis C virus and method for making same
WO1992001714A1 (fr) † 1990-07-24 1992-02-06 Yamanouchi Pharmaceutical Co., Ltd. Antigene du virus de l'hepatite non a, non b
JP3114731B2 (ja) * 1990-08-14 2000-12-04 国立感染症研究所長 Ｃ型肝炎ウイルス抗体検出用ペプチド抗原及びその使用方法
JPH04300000A (ja) * 1991-03-27 1992-10-23 Teijin Ltd 核酸の定量方法
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AU4248193A (en) † 1992-05-15 1993-12-13 New England Deaconess Hospital Quantitation of viral rna by competitive polymerase chain reaction
EP0586112A3 (en) * 1992-08-14 1994-09-14 Pharma Gen S A Control of pcr mediated detection of micro-organisms
DE69332852T2 (de) * 1992-09-11 2003-12-04 F. Hoffmann-La Roche Ag, Basel Nachweis von Nukleinsäuren im Blut
CA2159044A1 (en) * 1994-09-26 1996-03-27 Falko-Guenter Falkner Method of quantitating nucleic acids

Also Published As

Publication number Publication date
NO322186B1 (no) 2006-08-28
JP2008247913A (ja) 2008-10-16
NO970050L (no) 1997-01-07
DK0769954T4 (da) 2011-04-04
ES2203688T5 (es) 2011-07-01
IL118188A0 (en) 1996-09-12
DE59610626D1 (de) 2003-09-04
WO1996035437A1 (de) 1996-11-14
ES2203688T3 (es) 2004-04-16
CA2191475C (en) 2010-09-14
ATE245989T1 (de) 2003-08-15
EP0769954A1 (de) 1997-05-02
ATA77895A (de) 1999-06-15
EP0769954B2 (de) 2011-03-09
JPH10502943A (ja) 1998-03-17
CA2191475A1 (en) 1996-11-14
NO970050D0 (no) 1997-01-07
EP0769954B1 (de) 2003-07-30
IL118188A (en) 2000-07-16
AT406019B (de) 2000-01-25

Similar Documents

Publication Publication Date Title
DK0769954T4 (da) Kvalitetssikret lægemiddel indeholdende et eller flere plasmaderivater
ZA966751B (en) Novel acyl derivatives of melatonin and of metalotoninergic analogues; process for their preparation and their use as medicinal products.
HUP9801151A2 (hu) Stabilan tárolható gyógyszerformák
ES2138661T3 (es) Formulaciones de dosis elevadas.
ATE316100T1 (de) Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
PT710124E (pt) Metodo de esterilizacao de produtos
HUT61296A (en) Process for producing substituted diaromatic compounds against aids and pharmaceutical compositions comprising same
HU9402238D0 (en) 1-benzenesulfonyl-1,3-dihydro-2h-benzimidazol-2-one derivatives, process for producing them and pharmaceutical compositions containing them
PL318282A1 (en) Benzoyl derivatives and method of obtaining them
KR960700723A (ko) Aids-관련 신경 장애를 치료하기 위한 카르바마제핀 및 옥스카르바제핀과 같은 항간질제의 사용(use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders)
ATE213164T1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
MY109594A (en) Acetamide derivatives.
PT98371A (pt) Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
NO971323L (no) Framgangsmåte for framstilling av stivelsesnedbrytningsprodukt
DE59611111D1 (de) Phospholipid-derivate von phosphonocarbonsäuren, deren herstellung sowie deren verwendung als antivirale arzneimittel
ATE123945T1 (de) Verwendung von fluor enthaltenden pyridoncarbonsäure-derivaten zur herstellung eines arzneimittels zur behandlung von hiv infektionen.
IL88971A (en) Disubstituted pyridines, process and intermediates, their preparation and pharmaceutical compositions containing them
HUT57205A (en) Process for producing cycloalkano/b/-indol derivatives and pharmaceutical compositions containing them
ATE137237T1 (de) R-(-)-1-(5-hydroxyhexyl)-3-methyl-7- propylxanthin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
ATE65778T1 (de) 4-oxo-thiazolidin-2-yliden-acetamid-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel zur bekaempfung von erkrankungen des zentralnervensystems.
HUT58282A (en) Process for producing new, cyclic ketone derivatives and pharmaceutical compositions containing them as active components
ATE243683T1 (de) Polyhydroxybutylpyrazinen, deren herstellung und diese enthaltende arzneimitteln
FI97225C (fi) Menetelmä terapeuttisesti käyttökelpoisten (4-amino-2,6-dimetyylifenyylisulfonyyli)nitrometaanijohdannaisten valmistamiseksi
AU1370897A (en) Process for gently sterilising pharmaceutical compositions